Acute Sleep Loss Triggers Increase in Plasma Levels of Tau Protein in Young Adults
By LabMedica International staff writers Posted on 20 Jan 2020 |

Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
A team of Swedish researchers has found that acute sleep loss results in increased blood levels of t-tau protein, a key biomarker for nervous system disorders such as Alzheimer’s disease.
Previous studies had shown that disrupted sleep increased CSF (cerebrospinal fluid) levels of tau and beta-amyloid (ABeta) and was associated with an increased risk of Alzheimer’s disease (AD). The aim of the current study, conducted by investigators at Uppsala University (Sweden), was to determine whether acute sleep loss altered diurnal profiles of plasma-based AD-associated biomarkers.
The current study involved 15 healthy, normal-weight men with an average age of 22 years. The design of the experiment comprised two phases. For each phase, the subjects were housed in a sleep clinic for two days and nights under a strict meal and activity schedule. Blood samples were collected in the evening and again in the morning. For one phase, participants were allowed an uninterrupted night of sleep both nights. For the other phase, participants were allowed uninterrupted sleep the first night followed by a second night of sleep deprivation.
Plasma levels of total tau (t-tau), ABeta40, ABeta42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in the blood samples were assessed using ultrasensitive single molecule array assays or ELISAs,
Results revealed the after sleep deprivation, the subjects had an average 17% increase in tau levels in their blood. In contrast, following a night of interrupted sleep, the subjects had an average increase in tau levels of only 2%. No changes between the sleep conditions were seen for levels of ABeta40, ABeta42, NfL, or GFAP.
"Many of us experience sleep deprivation at some point in our lives due to jet lag, pulling an all-nighter to complete a project, or because of shift work, working overnights. or inconsistent hours," said senior author Dr. Jonathan Cedernaes, a senior researcher at Uppsala University. "Our exploratory study shows that even in young, healthy individuals, missing one night of sleep results in a slight increase in the level of tau in blood. This suggests that over time, similar types of sleep disruption could potentially have detrimental effects."
"It is important to note that while accumulation of tau in the brain is not good, in the context of sleep loss, we do not know what higher levels of tau in blood represent" said Dr. Cedernaes. "When neurons are active, release of tau in the brain is increased. Higher levels in the blood may reflect that these tau proteins are being cleared from the brain or they may reflect an overall elevation of the concentration of tau levels in the brain. Future studies are needed to investigate this further, as well as to determine how long these changes in tau last, and to determine whether changes in tau in blood reflects a mechanism by which recurrent exposure to restricted, disrupted or irregular sleep may increase the risk of dementia. Such studies could provide key insight into whether interventions targeting sleep should begin at an early age to reduce a person's risk of developing dementia or Alzheimer's disease."
The study was published in the January 8, 2020, online edition of the journal Neurology.
Related Links:
Uppsala University
Previous studies had shown that disrupted sleep increased CSF (cerebrospinal fluid) levels of tau and beta-amyloid (ABeta) and was associated with an increased risk of Alzheimer’s disease (AD). The aim of the current study, conducted by investigators at Uppsala University (Sweden), was to determine whether acute sleep loss altered diurnal profiles of plasma-based AD-associated biomarkers.
The current study involved 15 healthy, normal-weight men with an average age of 22 years. The design of the experiment comprised two phases. For each phase, the subjects were housed in a sleep clinic for two days and nights under a strict meal and activity schedule. Blood samples were collected in the evening and again in the morning. For one phase, participants were allowed an uninterrupted night of sleep both nights. For the other phase, participants were allowed uninterrupted sleep the first night followed by a second night of sleep deprivation.
Plasma levels of total tau (t-tau), ABeta40, ABeta42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in the blood samples were assessed using ultrasensitive single molecule array assays or ELISAs,
Results revealed the after sleep deprivation, the subjects had an average 17% increase in tau levels in their blood. In contrast, following a night of interrupted sleep, the subjects had an average increase in tau levels of only 2%. No changes between the sleep conditions were seen for levels of ABeta40, ABeta42, NfL, or GFAP.
"Many of us experience sleep deprivation at some point in our lives due to jet lag, pulling an all-nighter to complete a project, or because of shift work, working overnights. or inconsistent hours," said senior author Dr. Jonathan Cedernaes, a senior researcher at Uppsala University. "Our exploratory study shows that even in young, healthy individuals, missing one night of sleep results in a slight increase in the level of tau in blood. This suggests that over time, similar types of sleep disruption could potentially have detrimental effects."
"It is important to note that while accumulation of tau in the brain is not good, in the context of sleep loss, we do not know what higher levels of tau in blood represent" said Dr. Cedernaes. "When neurons are active, release of tau in the brain is increased. Higher levels in the blood may reflect that these tau proteins are being cleared from the brain or they may reflect an overall elevation of the concentration of tau levels in the brain. Future studies are needed to investigate this further, as well as to determine how long these changes in tau last, and to determine whether changes in tau in blood reflects a mechanism by which recurrent exposure to restricted, disrupted or irregular sleep may increase the risk of dementia. Such studies could provide key insight into whether interventions targeting sleep should begin at an early age to reduce a person's risk of developing dementia or Alzheimer's disease."
The study was published in the January 8, 2020, online edition of the journal Neurology.
Related Links:
Uppsala University
Latest Molecular Diagnostics News
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more